The FDA has evidently learned all it wants at this point from its outside oncology experts on CAR-T. Kite Pharma’s closely-watched CAR-T drug axi-cel is getting a pass on an adcomm meeting, which may signal a quick thumbs up from regulators.
Kite execs think so, saying today that they will be fully launch-ready by September in case an early OK comes through.
